Download PDF
Horm Metab Res 2010; 42(11): 763-768
DOI: 10.1055/s-0030-1262825
Review

© Georg Thieme Verlag KG Stuttgart · New York

Diabetes and Bone

P. Pietschmann1 , J. M. Patsch1 , G. Schernthaner2
  • 1Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
  • 2Department of Medicine I, Rudolfstiftung Hospital, Vienna, Austria
Further Information

Publication History

received 03.02.2010

accepted 07.07.2010

Publication Date:
13 August 2010 (online)

Also available at
    Permissions and Reprints

Abstract

Traditionally, patients with type 1 diabetes were regarded to be at an increased risk of fractures whereas type 2 diabetics were assumed to be protected from fractures since many of them have high bone mineral density. Nevertheless, several clinical studies consistently demonstrated that type 2 diabetes is a paradigm of a disease with an increased risk of fractures in the presence of high bone mass. The pathophysiology of decreased bone strength in diabetes mellitus is multifactorial: insulin deficiency, insulin resistance, osteoblast insufficiency, vitamin D deficiency, formation of advanced glycation endproducts in bone, and microvascular complications appear to contribute. Drugs used for the treatment of type 2 diabetes also may influence bone fragility: thiazolidinedione use has been associated with an increased risk of fractures.

Key words

diabetes mellitus - advanced glycosylation endproducts - osteocalcin - thiazolidinediones - runx2 - PPARγ

References

  • 1 Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation.  Nature. 2003;  423 337-342
    Google Scholar
  • 2 Rauner M, Sipos W, Pietschmann. Osteoimmunology.  Int Arch Allergy Immunol. 2007;  143 31-48
    Google Scholar
  • 3 Sipos W, Pietschmann P, Rauner M, Kerschan-Schindl K, Patsch J. Pathophysiology of osteoporosis.  Wien Med Wochenschr. 2009;  159 230-234
    Google Scholar
  • 4 de Paula FJ, Rosen CJ. Back to the future: revisiting parathyroid hormone and calcitonin control of bone remodeling.  Horm Metab Res. 2010;  42 299-306
    Google Scholar
  • 5 Aubin JE, Lian JB, Stein GS. Bone formation: Maturation and functional activities of osteoblast lineage cells. In: American Society for Bone and Mineral Research. Primer on the metabolic bone diseases and disorders of mineral metabolism. 6th ed., Washington DC: ASBMR; 2006: 20-29
    Google Scholar
  • 6 Lecka-Czernik B, Suva LJ. Resolving the two “bony” faces of PPAR-gamma.  PPAR Res. 2006;  1-9
    Google Scholar
  • 7 Takada I, Suzawa M, Matsumoto K, Kato S. Suppression of PPAR-{gamma} transactivation switches cell fate of bone marrow stem cells from adipocytes into osteoblasts.  Ann N Y Acad Sci. 2007;  1116 182-195
    Google Scholar
  • 8 Anonymous . Osteoporosis prevention, diagnosis and therapy.  JAMA. 2001;  285 785-795
    Google Scholar
  • 9 Obermayer-Pietsch B. Genetics of Osteoporosis.  Wien Med Wochenschr. 2006;  156 162-167
    Google Scholar
  • 10 Hamdy NAT. Osteoporosis: Other Secondary Causes. In: Rosen CJ, (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism. 7th ed., Washington DC: ASBMR; 2008: 276-279
    Google Scholar
  • 11 Leidig-Bruckner G, Ziegler R. Diabetes mellitus a risk for osteoporosis?.  Exp Clin Endocrinol Diabetes. 2001;  109 (S 02) 493-514
    Google Scholar
  • 12 Lowe H, Shane E. Osteoporosis associated with illness and medications. In:, Marcus R, Feldman D, Nelson DA, Rosen CJ (eds) Osteoporosis. 3rd ed., Volume 2, New York: Academic Press; 2008: 1283-1314
    Google Scholar
  • 13 Dobnig H, Piswanger-Sölkner JC, Roth M, Obermayer-Pietsch B, Tiran A, Strele A, Maier E, Maritschnegg P, Sieberer C, Fahrleitner-Pammer A. Type 2 diabetes mellitus in nursing home patients: effects of bone turnover, bone mass, and fracture risk.  J Clin Endocrinol Metab. 2006;  91 3276-3278
    Google Scholar
  • 14 Miao J, Brismar K, Nyrén O, Ugarph-Morawski A, Ye W. Elevated hip fracture risk in type 1 diabetic patients: a population-based cohort study in Sweden.  Diabetes Care. 2005;  28 2850-2855
    Google Scholar
  • 15 Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, Johnson KC, Margolis KL. Risk of fracture in women with type 2 diabetes: the Women's health initiative observational study.  J Clin Endocrinol Metab. 2006;  91 3404-3410
    Google Scholar
  • 16 Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture.  Am J Epidemiol. 2007;  166 495-505
    Google Scholar
  • 17 Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes – a meta-analysis.  Osteoporos Int. 2007;  18 427-444
    Google Scholar
  • 18 Melton LJ, Leibson CL, Achenbach SJ, Therneau TM, Khosla S. Fracture risk in type 2 diabetes: update of a population-based study.  J Bone Miner Res. 2008;  23 1334-1342
    Google Scholar
  • 19 Yamamoto M, Yamaguchi T, Yamaguchi M, Kaji H, Sugimoto T. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications.  J Bone Miner Res. 2009;  24 702-709
    Google Scholar
  • 20 Hickman J, McElduff A. Insulin promotes growth of the cultured rat osteosarcoma cell line UMR-106-01: an osteoblast-like cell.  Endocrinology. 1989;  124 701-706
    Google Scholar
  • 21 Thomas DM, Hards DK, Rogers SD, Ng KW, Best JD. Insulin receptor expression in bone.  J Bone Miner Res. 1996;  11 1312-1320
    Google Scholar
  • 22 Thomas DM, Udagawa N, Hards DK, Quinn JM, Moseley JM, Findlay DM, Best JD. Insulin receptor expression in primary and cultured osteoclast-like cells.  Bone. 1998;  23 181-186
    Google Scholar
  • 23 Hock JM, Centrella M, Canalis E. Insulin-like growth factor I has independent effects on bone matrix formation and cell replication.  Endocrinology. 1988;  122 254-260
    Google Scholar
  • 24 Botolin S, McCabe LR. Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways.  J Cell Biochem. 2006;  99 411-424
    Google Scholar
  • 25 Botolin S, Faugere MC, Malluche H, Orth M, Meyer R, McCabe LR. Increased bone adiposity and peroxisomal proliferator-activated receptor-gamma2 expression in type I diabetic mice.  Endocrinology. 2005;  146 3622-3631
    Google Scholar
  • 26 Wittrant Y, Gorin Y, Woodruff K, Horn D, Abboud HE, Mohan S, Abboud-Werner SL. High d(+)glucose concentration inhibits RANKL-induced osteoclastogenesis.  Bone. 2008;  42 1122-1130
    Google Scholar
  • 27 Kawashima Y, Fritton JC, Yakar S, Epstein S, Schaffler MB, Jespen KJ, LeRoith D. Type 2 diabetic mice demonstrate slender long bones with increased fragility secondary to increased osteoclastogenesis.  Bone. 2009;  44 648-655
    Google Scholar
  • 28 Suzuki K, Kurose T, Takizawa M, Maruyama M, Ushikawa M, Sugimoto C, Seino Y, Nagamatsu S, Ishida H. Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIP/OPG) on the decrease of bone mineral density.  Diabetes Res Clin Pract. 2005;  68 117-125
    Google Scholar
  • 29 Patsch JM, Kiefer FW, Varga P, Pail P, Rauner M, Stupphann D, Resch H, Moser D, Zysset PK, Stulnig TM, Pietschmann P. Increased bone resorption and impaired bone architecture in short-term and extended high-fat diet-induced obesity.  Metabolism. 2010;  Feb. 19 [Epub ahead of print]
    Google Scholar
  • 30 Verhaeghe J, Suiker AM, Nyomba BL, Visser WJ, Einhorn TA, Dequeker J, Bouillon R. Bone mineral homeostasis in spontaneously diabetic BB rats. II. Impaired bone turnover and decreased osteocalcin synthesis.  Endocrinology. 1989;  124 573-582
    Google Scholar
  • 31 Verhaeghe J, Suiker AM, Visser WJ, Van Herck E, Van Bree R, Bouillon R. The effects of systemic insulin, insulin-like growth factor-I and growth hormone on bone groth and turnover in spontaneously diabetic BB rats.  J Endocrinol. 1992;  134 485-492
    Google Scholar
  • 32 Verhaeghe J, Oloumi G, van Herck E, van Bree R, Dequeker J, Einhorn TA, Bouillon R. Effects of long-term diabetes and/or high-dose 17 beta-estradiol on bone formation, bone mineral density, and strength in ovariectomized rats.  Bone. 1997;  20 421-428
    Google Scholar
  • 33 Verhaeghe J, Suiker AM, Einhorn TA, Geusens P, Visser WJ, Van Herck E, Van Bree R, Magistky S, Bouillon R. Brittle bones in spontaneously diabetic female rats cannot be predicted by bone mineral measurements: studies in diabetic and ovariectomized rats.  J Bone Miner Res. 1994;  9 1657-1667
    Google Scholar
  • 34 Glajchen N, Epstein S, Ismail F, Thomas S, Fallon M, Chakrabarti S. Bone mineral metabolism in experimental diabetes mellitus: osteocalcin as a measure of bone remodelling.  Endocrinology. 1988;  123 290-295
    Google Scholar
  • 35 Hamada Y, Kitazawa S, Kitazawa R, Fujii H, Kasuga M, Fukagawa M. Histomorphometric analysis of diabetic osteopenia in streptozotocin-induced diabetic mice: a possible role of oxidative stress.  Bone. 2007;  40 1408-1414
    Google Scholar
  • 36 Takeshita N, Ishida H, Yamamoto T, Koh G, Kurose T, Tsuji K, Okamoto Y, Ikeda H, Seino Y. Circulating levels and bone contents of bone gamma-carboxyglutamic acid-containing protein in rat models of non-insulin-dependent diabetes mellitus.  Acta Endocrinol (Copenh). 1993;  128 69-73
    Google Scholar
  • 37 Prisby RD, Swift JM, Bloomfield SA, Hogan HA, Delp MD. Altered bone mass, geometry and mechanical properties during the development and progression of type 2 diabetes in the Zucker diabetic fatty rat.  J Endocrinol. 2008;  199 379-388
    Google Scholar
  • 38 Silva MJ, Brodt MD, Lynch MA, McKenzie JA, Tanouye KM, Nyman JS, Wang X. Type 1 diabetes in young rats leads to progressive trabecular bone loss, cessation of cortical bone growth, and diminished whole bone strength and fatigue life.  J Bone Miner Res. 2009;  24 1618-1627
    Google Scholar
  • 39 Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus.  Osteoporos Int. 2010;  21 195-214
    Google Scholar
  • 40 Tang SY, Vashishth D. Non-enzymatic glycation alters microdamage formation in human cancellous bone.  Bone. 2009;  46 148-154
    Google Scholar
  • 41 Kruse K, Kracht U. Evaluation of serum osteocalcin as an index of altered bone metabolism.  Eur J Pediatr. 1986;  145 27-33
    Google Scholar
  • 42 Pietschmann P, Schernthaner G, Woloszczuk W. Serum osteocalcin levels in diabetes mellitus: analysis of the type of diabetes and microvascular complications.  Diabetologia. 1988;  31 892-895
    Google Scholar
  • 43 Rico H, Hernandez ER, Cabranes JA, Gomez-Castresana F. Suggestion of a deficient osteoblastic function in diabetes mellitus: the possible cause of osteopenia in diabetics.  Calcif Tissue Int. 1989;  45 71-73
    Google Scholar
  • 44 Pedrazzoni M, Ciotti G, Piolo G, Girasole G, Davoli L, Palummeri E, Passeri M. Osteocalcin levels in diabetic subjects.  Calcif Tissue Int. 1989;  45 331-336
    Google Scholar
  • 45 Gregorio F, Cristallini S, Santeusanio F, Filipponi P, Fumelli P. Osteopenia associated with non-insulin-dependent diabetes mellitus: what are the causes?.  Diabetes Res Clin Pract. 1994;  23 43-54
    Google Scholar
  • 46 Pietschmann P, Kerschan-Schindl K. Osteoporosis: Gender-specific aspects.  Wien Med Wochenschr. 2004;  154 411-415
    Google Scholar
  • 47 Burkhardt R, Kettner G, Böhm W, Schmidmeier M, Schlag R, Frisch B, Mallmann B, Eisenmenger W, Gilg T. Changes in trabecular bone, hematopoiesis and bone marrow vessels in aplastic anemia, primary osteoporosis, and old age: a comparative histomorphometric study.  Bone. 1987;  8 157-164
    Google Scholar
  • 48 Prisby RD, Ramsey MW, Behnke BJ, Dominguez 2nd JM, Donato AJ, Allen MR, Delp MD. Aging reduces skeletal blood flow, endothelium-dependent vasodilation, and NO bioavailability in rats.  J Bone Miner Res. 2007;  22 1280-1288
    Google Scholar
  • 49 Mathiassen B, Nielsen S, Johansen JS, Hartwell D, Ditzel J, Rødbro P, Christiansen C. Long-term bone loss in insulin-dependent diabetic patients with microvascular complications.  J Diabet Complications. 1990;  4 145-149
    Google Scholar
  • 50 Jehle PM, Jehle DR, Mohan S, Böhm BO. Serum levels of insulin-like growth factor system components and relationship to bone metabolism in type 1 and type 2 diabetes mellitus patients.  J Endocrinol. 1998;  159 297-306
    Google Scholar
  • 51 Zayour D, Daouk M, Medawar W, Salamoun M, El-Hajj Fuleihan G. Predictors of bone mineral density in patients on hemodialysis.  Transplant Proc. 2004;  36 1297-1301
    Google Scholar
  • 52 Malluche HH, Mawad H, Monier-Faugere MC. The importance of bone health in end-stage renal disease: out of the frying pan, into the fire?.  Nephrol Dial Transplant. 2004;  19 (S 01) 9-13
    Google Scholar
  • 53 Hoskins B, Scott JM. Evidence for a direct action of insulin to increase renal reabsorption of calcium and for an irreversible defect in renal ability to conserve calcium due to prolonged absence of insulin.  Diabetes. 1984;  33 991-994
    Google Scholar
  • 54 Malone JI, Lowitt S, Duncan JA, Shah SC. Hematuria and hypercalciuria in children with diabetes mellitus.  Pediatrics. 1987;  79 756-759
    Google Scholar
  • 55 Harangi F, Soltész G, Mèhes K. Hypercalciuria in children with diabetes mellitus.  Helv Paediatr Acta. 1989;  43 267-271
    Google Scholar
  • 56 Ponder SW, Brouhard BH, Travis LB. Hyperphosphaturia and hypermagnesuria in children with IDDM.  Diabetes Care. 1990;  13 437-441
    Google Scholar
  • 57 Sufliarska A, Michalkovà D, Tomecková E, Silesová J, Lenková N, Kovács L. Microalbuminuria and tubular reabsorption of mineral in children with type 1 diabetes mellitus.  Bratisl Lek Listy. 1998;  99 26-32
    Google Scholar
  • 58 Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis.  J Clin Endocrinol Metab. 2007;  92 2017-2029
    Google Scholar
  • 59 Targher G, Bertolini L, Padovani R, Zenari L, Scala L, Cigolini M, Arcaro G. Serum 25-hydroxyvitamin D3 concentrations and carotid artery intima-media thickness among type 2 diabetic patients.  Clin Endocrinol. 2006;  65 593-597
    Google Scholar
  • 60 Peterlik M, Cross HS. Vitamin D and calcium deficits predispose for multiple chronic diseases.  Eur J Clin Invest. 2005;  35 290-304
    Google Scholar
  • 61 Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G. Endocrine regulation of energy metabolism by the skeleton.  Cell. 2007;  130 456-469
    Google Scholar
  • 62 Sottile V, Seuwen K, Kneissel M. Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone).  Calcif Tissue Int. 2004;  75 329-337
    Google Scholar
  • 63 Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation.  Endocrinology. 2005;  146 1226-1235
    Google Scholar
  • 64 Benvenuti S, Cellai I, Luciani P, Deledda C, Baglioni S, Giuliani C, Saccardi R, Mazzanti B, Dal Pozzo S, Mannucci E, Peri A, Serio M. Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells.  J Endocrinol Invest. 2007;  30 RC26-RC30
    Google Scholar
  • 65 Gustafson B, Eliasson B, Smith U. Thiazolidinediones increase the wingless-type MMTV integration site family (WNT) inhibitor Dickkopf-1 in adipocytes: a link with osteogenesis.  Diabetologia. 2009;  53 5536-5540
    Google Scholar
  • 66 Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O’Neill MC, Zinman B, Viberti G, ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.  N Engl J Med. 2006;  355 2427-2443
    Google Scholar
  • 67 Yaturu S, Bryant B, Jain SK. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men.  Diabetes Care. 2007;  30 1574-1576
    Google Scholar
  • 68 Berberoglu Z, Gursoy A, Bayraktar N, Yazici AC, Bascil Tutuncu N, Guvener Demiarag N. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women.  J Clin Endocrinol Metab. 2007;  92 3523-3530
    Google Scholar
  • 69 Zinman B, Haffner SM, Herman WH, Holman RR, Lachin JM, Kravitz BG, Paul G, Jones NP, Aftring RP, Viberti G, Kahn SE, A Diabetes Outcome Progression Trial Study Group. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.  J Clin Endocrinol Metab. 2010;  95 134-142
    Google Scholar
  • 70 Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jone NP, Komajda M, McMurray JJ. RECORD Study Team . Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.  Lancet. 2009;  373 (9681) 2125-2135
    Google Scholar
  • 71 Mancini T, Mazziotti G, Doga M, Carpinteri R, Simetovic N, Vescovi PP, Giustina A. Vertebral fractures in males with type 2 diabetes treated with rosiglitazone.  Bone. 2009;  45 784-788
    Google Scholar
  • 72 Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinesdiones and fracture in type 2 diabetes: a meta-analysis.  CMAJ. 2009;  180 32-39
    Google Scholar
  • 73 Dormuth CR, Carney G, Carleton B, Bassett K, Wright JM. Thiazolidinediones and fracture in men and women.  Arch Intern Med. 2009;  169 1395-1402
    Google Scholar
  • 74 Douglas IJ, Evans SJ, Pocok S, Smeeth L. The risk of fractures associated with thiazolidinediones: a self-controlled case-series study.  PLoS Med. 2009;  6 e1000154 DOI: doi: 10.1371/journal.pmed.1000154
    Google Scholar
  • 75 Habib ZA, Havstad SL, Wells K, Divine G, Pladevall M, Williams LK. Thiazolidinediones use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus.  J Clin Endocrinol Metab. 2010;  95 592-600
    Google Scholar
  • 76 Hsiao FY, Mullins CD. The association between thiazolidinediones and hospitalisation for fracture in type 2 diabetic patients: a Taiwanese population-based nested case-control study.  Diabetologia. 2010;  53 489-496
    Google Scholar
  • 77 Dagdelen S, Sener D, Bayraktar M. Influence of type 2 diabetes mellitus on bone mineral density response to bisphosphonates in late postmenopausal osteoporosis.  Adv Ther. 2007;  24 1314-1320
    Google Scholar

Correspondence

P. PietschmannMD 

Associate Professor

Department of Pathophysiology

and Allergy Research

Center of Pathophysiology,

Infectiology and Immunology

Medical University of Vienna

Währinger Gürtel 18–20

1090 Vienna

Austria

Phone: +43/140/400 5126

Fax: +43/140/400 5130

Email: peter.pietschmann@meduniwien.ac.at